Please assess the completion status of the following clinical trial:

Trial Title: EVL (Endoscopic Variceal Ligation) Plus Vasoconstrictor vs.Ligation Plus PPI( Proton Pump Inhibitor) in the Control of Acute Esophageal Variceal Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The etiology of portal hypertension is cirrhosis.~* Age ranges between 18-80 y/o.~* Patients presenting with acute esophageal variceal bleeding proven by emergency endoscopy within 12 hours. (Acute esophageal variceal bleeding was defined as: (1) when blood was directly seen by endoscopy to issue from an esophageal varix (active bleeding), or (2) when patients presented with red color signs on their esophageal varices with blood in esophagus or stomach and no other potential site of bleeding identified (inactive bleeding).~* EVL is performed after confirmation of acute esophageal variceal bleeding. Enrollment time: Immediately after EVL is completed and variceal bleeding is arrested.~Exclusion Criteria:~* Association with severe systemic illness, such as sepsis, COPD, uremia~* Association with gastric variceal bleeding~* Failure in the control of bleeding by emergency EVL~* Moribund patients, died within 12 hours of enrollment~* Uncooperative~* Ever received EIS, EVL within one month prior to index bleeding~* Child-Pugh's scores \> 13

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- EVL + vasoconstrictor (Type: ACTIVE_COMPARATOR): Somatostatin 6mg in 500 cc 5% dextrose, 250μg slow bolus IV infusion followed by 250μg per hour (6mg/ 24 hours) or Terlipressin 2mg bolus was instituted on enrollment followed by 1mg per 6 hours for 5 days. The use of either somatostatin or glypressin was at the discretion of doctors in charge.
- EVL + PPI (Type: EXPERIMENTAL): Pantoloc 40 mg intravenously per day was instituted on enrollment and continued for 5

Based on this trial design, predict the completion outcome and termination type (if applicable).